1408075-33-1

Basic information

• Product Name: tert-butyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate
• Synonyms: tert-butyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate
• CAS NO: 1408075-33-1
• Molecular Weight: 539.464
• Mol File: 1408075-33-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate(1408075-33-1)
• EPA Substance Registry System: tert-butyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate(1408075-33-1)

Safety Data

• Hazardous Substances Data: 1408075-33-1(Hazardous Substances Data)

Upstream product

• 106-47-8 4-chloro-aniline 
• 103505-49-3 6-chloro-N₄-(4-chlorophenyl)-4,5-pyrimidinediamine 
• 686344-50-3 6-chloro-9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purine 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Downstream Products

• 1408075-50-2 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}acetamide 
• 1408075-37-5 1-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-3-ethylurea 
• 1450979-68-6 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}aminosulfonamide 
• 1450979-69-7 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-1,1,1-trifluoromethanesulfonamide 
• 1450979-70-0 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}cyclohexanecarboxamide 
• 1450979-77-7 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-3-(piperidin-1-yl)propanamide 
• 1450979-79-9 methyl N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}carbamate 
• 1408075-54-6 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}methanesulfonamide 
• 1408075-60-4 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}benzamide 
• 1408075-57-9 N-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-2,2,2-trifluoroacetamide 
• 1408075-47-7 3-butyl-1-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}urea 
• 1408075-43-3 1-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-3-propylurea 
• 1408075-40-0 1-{1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]piperidin-4-yl}-3-(propan-2-yl)urea 
• 1408075-34-2 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-piperidin-4-amine 

Relevant articles and documents

Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor

Peripherally restricted CB1 receptor antagonists may be useful in treating metabolic syndrome, diabetes, liver diseases, and gastrointestinal disorders. Clinical development of the centrally acting CB1 inverse agonist otenabant (1) was halted due to its p

PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES

The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.